A two-dose regimen of Qβ virus-like particle-based vaccines elicit protective antibodies against heroin and fentanyl
Romano, I. G.; Johnson-Weaver, B. T.; Core, S. B.; Jamus, A. N.; Brackeen, M.; Blough, B.; Dey, S.; Huang, Y.; Staats, H. F.; Wetsel, W. C.; Chackerian, B.; Frietze, K. M.
Show abstract
Opioid overdoses and the growing rate of opioid use disorder (OUD) are major public health concerns, particularly in the United States. Current treatment approaches for OUD have failed to slow the growth of the opioid crisis. Opioid vaccines have shown pre-clinical success in targeting multiple different opioid drugs. However, the need for many immunizations can limit their clinical implementation. In this study, we investigate the development of novel opioid vaccines by independently targeting fentanyl and the active metabolites of heroin using a bacteriophage virus-like particle (VLP) vaccine platform. We establish the successful conjugation of haptens to bacteriophage Q{beta} VLPs and demonstrate immunogenicity of Q{beta}-fentanyl, Q{beta}-morphine, and Q{beta}-6-acetylmorphine in animal models after one or two immunizations. We show that in independently or in combination, these vaccines elicit high-titer, high-avidity, and durable antibody responses. Moreover, we reveal their protective capacities against heroin or fentanyl challenge after two immunizations. Overall, these findings establish Q{beta}-VLP conjugated vaccines for heroin and fentanyl as very promising opioid vaccine candidates.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability 95%
- Enhanced protective efficacy of a novel, thermostable, RBD-S2 fusion immunogen against SARS-CoV-2 and its variants 94%
- Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model 93%
Similar papers in this journal
- A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection. 94%
- Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine 93%
- TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination 93%
Similar papers in this journal
- A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses 94%
- Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates 93%
- SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice 93%
Similar papers in this journal
- The Dual-Antigen Ad5 COVID-19 Vaccine Delivered as an Intranasal Plus Subcutaneous Prime Elicits Th1 Dominant T-Cell and Humoral Responses in CD-1 Mice 93%
- Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals 93%
- Inhibiting Spinal Cord-Specific Hsp90 Isoforms Reveals a Novel Strategy to Improve the Therapeutic Index of Opioid Treatment 93%
Similar papers in this journal
- Refined Tamoxifen Administration in Mice by Encouraging Voluntary Consumption of Palatable Formulations. 92%
- Diet gel-based oral drug delivery system for controlled dosing of small molecules for microglia depletion and inducible Cre recombination in mice 89%
- Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.